Developmental Hemostasis: Relevance to Thromboembolic Complications in Pediatric Patients

Maureen Andrew

doi:10.1055/s-0038-1642714

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1995; 74(01): 415-425
DOI: 10.1055/s-0038-1642714

Symposium

Perinatal Haemostasis

Schattauer GmbH Stuttgart

Developmental Hemostasis: Relevance to Thromboembolic Complications in Pediatric Patients

Maureen Andrew

Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada

› Institutsangaben

Abstract

als PDF herunterladen

PDF (671 kb)

Referenzen

References
1 David M, Andrew M. Venous thromboembolism complications in children: A Critical Review of the Literature. J Pediatr 1993; 123: 337-346
2 Wise RC, Todd JK. Spontaneous, lower-extremity venous thrombosis in children. AJDC 1973; 126: 766-769
3 Bernstein D, Coupey S, Schonberg S. Pulmonary embolism in adolescents. Am J Dis Child 1986; 140: 667-671
4 Schmidt B, Andrew A. A prospective international registry of neonatal thrombotic diseases. Pediatr Res 1994; 35 Part 2 170a (abstract)
5 Andrew M, David M, Adams M. et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-1257
6 Coon W, Willis P, Keller J. Venous thromboembolism and other venous disease in the Tecumseh Community Health Study. Circulation 1973; 48: 839
7 Gjores J. The incidence of venous thrombosis and its sequelae in certain districts in Sweden. Acta Chir Scand 1956; Supp (Suppl. 01) 206: l
8 Carter C, Gent M. The epidemiology of venous thrombosis. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman R, Hirsh J, Marder V, Salzman E. (eds.) J.B. Lippincott Company; Philadelphia: 1982. pp 805-819
9 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574
10 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin:. overview of results of randomized trials in general, orthopedic, and urologic surger. N Engl J Med 1988; 318: 1162-1173
11 Clagett G, Reisch J. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-240
12 Planes A, Vochelle N, Mansat C. Prevention of deep vein thrombosis after total hip replacement by enoxaparin: one daily injection of 40 mg versus two daily injections of 20 mg. Thromb Haemostas 1987; Supp (Suppl. 01) 1: 415
13 Hull R, Delmore T, Hirsh J. et al. Effectiveness of an intermittent pulsatile elastic stocking for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 1979; 16: 37
14 Leclerc J, Desjardins L, Geerts W, Jobin F, Delorme F, Bourgouin J. A randomized trial of enoxaparin for the prevention of deep vein thrombosis after major knee surgery. Thromb Haemostas 1991; 65 Suppl 753
15 Uden A. Thromboembolic complications following scoliosis surgery in Scandinavia. Acta Orthop Scand 1979; 50: 175-178
16 Bauer K, Rosenberg R. The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
17 Hathaway W, Corrigan J. Report of scientific and standardization subcommittee on neonatal hemostasis. Thromb Haemostas 1991; 65: 323-325
18 Corrigan J. Normal hemostasis in fetus and newborn: Coagulation. In: Fetal and Neonatal Physiology. Polin R, Fox W. (eds.) W.B. Saunders; Philadelphia: 1992. pp 1368-1371
19 Hathaway WE, Bonnar J. Hemostatic disorders of the pregnant woman and newborn infant. Elsevier Science Publishing Co; New York: 1987
20 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172
21 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72: 1651-1657
22 Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104
23 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005
24 Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemostas 1990; 63: 27-30
25 Vieira A, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: An explanation. Thromb Res 1991; 63: 85-99
26 Schmidt B, Ofosu F, Mitchell L, Brooker L, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-408
27 Bussel J, Berkowitz R, McFarland J, Lynch L, Chitkara U. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl I Med 1988; 319: 1374-1378
28 Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemostas. 1994 in press
29 Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemostas 1989; 62: 788-791
30 Ganrot P, Schersten B. Serum α₂-macroglobulin concentration and its variation with age and sex. Clin Chim Acta 1967; 15: 113-120
31 Aballi A, de Lamerens S. Coagulation changes in the neonatal period and in early infancy. Pediatr Clin North Am 1962; 9: 785-817
32 Bleyer W, Hakami N, Shepard T. The development of hemostasis in the human fetus and newborn infant. J Pediatr 1971; 79: 838-853
33 Hathaway WE, Bonnar J. Bleeding disorders in the newborn infant. In: Oliver T KJ. (ed.) Perinatal Coagulation. Monographs in Neonatology; Grune and Stratton, New York: 1978. pp 115-169
34 Gross S, Stuart M. Hemostasis in the premature infant. Clin Perinatol 1977; 4: 259-304
35 Buchanan GR. Neonatal coagulation: normal physiology and pathophysiology. Clin Haematol 1978; 1: 85-109
36 Montgomery R, Marlar R, Gill J. Newborn Haemostasis. Clin Hematol 1985; 14: 443-460
37 Gibson B. Neonatal haemostasis. Arch Dis Child 1989; 64: 503-506
38 Gobel U, Voss HC, Petrich C, Jurgens H, Oliver A. Etiopathology and classification of acquired coagulation disorders in the newborn infant. Klinische Wochenschrift 1979; 57: 81-86
39 Buchanan G. Coagulation disorders in the neonate. Pediatr Clin North Am 1986; 33: 203-220
40 McDonald M, Hathaway W. Neonatal haemorrhage and thrombosis. Semin Perinatol 1983; 7: 213-225
41 Strothers J, Boulton F, Wild R. et al. Neonatal coagulation (letter). Lancet 1975; 1: 408-409
42 Bahakim H, Gader A, Gaiil A, Babbar FA, Gaafar TH, Edrees Y B. Coagulation parameters in maternal and cord blood at delivery. Ann Saudi Med 1990; 10: 149-155
43 Peters M, Jansen E, ten Cate JW, Kahle LH, Ockelford P, Breeder-veld C. Neonatal antithrombin III. Br J Haematol 1984; 58: 579-587
44 Manco-Johnson M. Neonatal antithrombin III deficiency. Am J Med 1989; 87 Supp (Suppl. 03) B 49S-52S
45 Greffe BS, Marlar RA, Manco-Johnson M. Neonatal protein C: Molecula composition and distribution in normal term infants. Thromb Res 1989; 56: 91
46 Manco-Johnson M, Nuss R, Jacobson L, Hathaway W. Activated protein C cofactor activity is increased in neonates. Blood 1994; 84 Suppl (Suppl. 10) 85a Abstract
47 Moalic P, Gruel Y, Body G, Foloppe P, Dalahousse B, Leroy J. Levels and plasma distribution of free and c4b-BP-bound Protein S in human fetuses and fullterm newborns. Thromb Res 1988; 49-471
48 Schwarz HP, Muntean W, Watzke H, Richter B, Griffin JH. Low total protein S antigen but high protein S activity due to decreased c4b-binding protein in neonates. Blood 1988; 71: 562
49 Aurousseau M, Amiral J, Boffa M. Level of plasma thrombomodulin in neonates and children. Thromb Haemostas 1991; 65: 1232 Abstract
50 Schmidt B, Mitchell L, Ofosu F, Andrew M. Alpha-2-macroglobu-lin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Thromb Haemostas 1989; 62: 1074-1077
51 Shah JK, Mitchell LG, Paes B, Ofosu FA, Schmidt B, Andrew M. Thrombin inhibition is impaired in plasma of sick neonates. Pediatr Res 1992; 31: 391-395
52 Andrew M, Mitchell L, Paes B. et al. An anticoagulant dermatan sulphate proteoglycan circulates in the pregnant women and her fetus. J Clin Invest 1992; 89: 321-326
53 Muller AD, Van Doorm JM. Heparin like inhibitor of blood coagulation in normal newborn. Nature 1977; 267: 616-617
54 Matzch T, Bergqvist D, Bergqvist A. et al. No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin. Blood Coagulation and Fibrinolysis 1991; 2: 273-278
55 Mitchell L, Piovella F, Ofosu F, Andrew M. alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III deficient children. Blood 1991; 78: 2299-2304
56 Witt I, Muller H, Kunter LJ. Evidence for the existence of fetal fibrinogen. Thromb Diath Haemorrh 1969; 22: 101-109
57 Hamulyak K, Nieuwenhuizen W, Devillee PP, Hemker HC. Re-evaluation of some properties of fibrinogen purified from cord blood of normal newborns. Thromb Res 1983; 32: 301-320
58 Galanakis DK, Mosesson MW. Evaluation of the role of in vivo proteolysis (fibrinogenolysis) in prolonging the thrombin time of human umbilical cord fibrinogen. Blood 1976; 48: 109-118
59 Yuen P MP, Yin JA, Lao T TH. Fibrino-peptide A levels in maternal and newborn plasma. Eur J Obstet Gynecol 1989; 30: 239
60 Suarez CR, Gonzalez J, Menendez C, Fareed J, Fresco R, Walenga J. Neonatal and maternal platelets: Activation at time of birth. Am J Hematol 1988; 29: 18-21
61 Suarez CR, Menendez CE, Walenga JM, Fareed J. Neonatal and maternal hemostasis. Value of molecular markers in the assessment of hemostatic status. Semin Thromb Haemostas 1984; 10: 280-284
62 Kisker C, Robillard J, Clarke W. Development of blood coagulations fetal lamb model. Pediatr Res 1981; 15: 1045-1050
63 Andrew M, O’Brodovich H, Mitchell L. The fetal lamb coagulation system during normal birth. Am J Hematol 1988; 28: 116-118
64 Bauer K, Weiss L, Sparrow D, Vokonas P, Rosenberg R. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 1987; 80: 1527-1534
65 Corrigan J. Neonatal thrombosis and the thrombolytic system. Pathophysiology and therapy. Am J Pediatr Hematol/Oncol 1988; 10: 83-91
66 Corrigan J, Sluth J, Jeter M, Lox C. Newborn’s fibrinolytic mechanism: Components and plasmin generation. AmJ Hematol 1989; 32: 273-278
67 Kolindewala JK, Das BK, Dube B, Bhargava B. Blood fibrinolytic activity in neonates: Effect of period of gestation birth weight, anoxia and sepsis. Ind Pediatr 1987; 24: 1029
68 Runnebaum IB, Maurer SM, Daly L, Bonnar J. Inhibitors and activators of fibrinolysis during and after childbirth in maternal and cord blood. J Perinatal Med 1989; 17: 113
69 Ambrus C, Jung O, Ambrus J, Mirand E, Choi T, Bartfay-Szabo A. The fibrinolysin system and its relationship to disease in the newborn. Am J Pediatr Hematol Oncol 1979; 1: 251-260
70 Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989; 61: 189-196
71 Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein J Clin Invest 1990; 86: 107-112
72 Summaria L. Comparison of human normal, full-term, fetal and adult plasminogen by physical and chemical analyses. Haemostasis 1989; 19: 266-273
73 Lecander I, Astedt B. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood. J Lab Clin Med 1987; 110: 602-605
74 Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemostas 1988; 60: 361-364
75 Andrew M, Brooker L, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemostas 1992; 68: 325-330
76 Markarian M, Githens J, Jackson J. et al. Fibrinolytic activity in premature infants. Relationship of the enzyme system to the respiratory distress syndrome. Amer J Dis Child 1967; 113: 312-321
77 Ekelund H, Hedner U, Nilsson I. Fibrinolysis in newborns. Acta Paediatr Scand 1970; 59: 33-43
78 Suarez CR, Walenga J, Mangogna LC, Fareed J. Neonatal and maternal fibrinolysis: Activation at time of birth. Am J Haem 1985; 19: 365
79 Beverley DW, Inwood MJ, Chance GW, Schaus M, O’Keefe B. “Normal” haemostasis parameters: A study in a well-defined inborn population of preterm infants. Ear Hum Devt 1984; 9: 249-257
80 Forestier F, Daffos F, Galacteros F, Bardakjian J, Rainaut M, Berezard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986; 20: 342-346
81 Arad ID, Alpan G, Sznajderman SD, Eldor A. The mean platelet volume (MVP) in the neonatal period. Am J Perinatol 1986; 3: 1-3
82 Kipper S, Sieger L. Whole blood platelet volumes in newborn infants. J Pediatr 1982; 101: 763-766
83 Gruel Y, Boizard B, Daffos F, Forestier F, Caen J, Wautier J. Determinations of platelet antigens and glycoproteins in the human fetus. Blood 1986; 68: 488-492
84 Katz J, Moake J, McPherson P, Weinstein M, Moise K. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma. Blood 1989; 73: 1851-1858
85 Weinstein M, Blanchard R, Moake J, Vosburgh E, Moise K. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenia purpura. Br J Haematol 1989; 72: 68-72
86 Ts’ao C, Green D, Schultz K. Function and ultrastructure of platelets of neonates; enhanced ristocetin aggregation of neonatal platelets. Br J Haematol 1976; 32: 225-233
87 Hrodek O. Blood platelets in the newborn: their function in haemostasis and haemocoagulation. Acta Universitatis Carolinae. 1966 Monograph 22
88 Corby D, O’Barr T. Decreased alpha-adrenergic receptors in newborn platelets. Cause of abnormal response to epinephrine Devt Pharm Therapeutics 1981; 2: 215-225
89 Stuart M, Dusse J, Clark A, Walenga R. Differences in thromboxane production between neonatal and adult platelets in response to arachidonic acid and epinephrine. Pediatr Res 1984; 18: 823-826
90 Alebouyeh M, Lusher J, Ameri M, Evans R, Robinson A. The effect of 5-hydroxytryptamine and epinephrine on newborn platelets. Eur J Pediatr 1978; 128: 163-168
91 Jones CR, McCabe R, Hamilton CA, Reid JL. Maternal and fetal platelet responses and adrenoreceptor binding characteristics. Thromb Haemostas 1985; 53: 95-98
92 Ahlsten G, Ewald U, Tuvemo T. Arachidonic acid induced aggregation of platelet from human cord blood compared with platelets from adults. Biol Neonate 1985; 47: 199-204
93 Barradas MA, Mikhailidis DP. An investigation of maternal and neonatal platelet function. Bio Res Pregnancy Perinatol 1986; 7: 60-65
94 Gader AMA, Bahakim H, Jabber FA, Lambourne AL, Gaafar TH. Dose-response aggregometry in maternal/neonatal platelets. Thromb Haemostas 1988; 60: 314-318
95 Andrews NP, Pipkin FB, Hepinstall S. Blood platelet behaviour in mothers and neonates. Thromb Haemostas 1985; 53: 428-432
96 Israels SJ, Daniels M, McMillan EM. Deficient collagen-induced activation in the newborn platelet. Pediatr Res 1990; 27: 337-343
97 Saving K, Aldag J, Jennings D, Caughey B, Regan M, Powers W. Electron microscopic characterization of neonatal platelet ultrastructure: Effects of sampling techniques. Thromb Res 1991; 61: 65-80
98 Corby DG, O’Barr TP. Neonatal platelet function: A membrane- -related phenomenon. Haemostasis 1981; 10: 177-185
99 Israels SJ, Gowen B, Gerrard JM. Contractile activity of neonatal platelets. Pediatr Res 1987; 21: 293-295
100 Stuart MJ, Wu J, Sunderji S, Cranley C. Effect of amniotic fluid on platelet thromboxane production. J Pediatr 1987; 110: 289-292
101 Jacqz EM, Barrow SE, Dollery CT. Prostacyclin concentrations in cord blood and in the newborn. Pediatrics 1985; 76: 954-957
102 Beckton D, Kinney T, Chaffee S, Kurtzberg J, Friedman H, Falletta J. High-dose intravenous immunoglobulin for severe platelet alloimmunization. Pediatrics 1984; 74: 1120-1122
103 Xu L, Delorme M, Berry L. et al. Alpha-2-macroglobulin remains as important as ATIII for thrombin regulation in cord plasma in the presence of endothelial cell surfaces. Pediatr Res. 1995 in press
104 Abman SH. Curr Opinion in Pediatr. 1994; 6: 239-247
105 Roze JC, Storme L, Zupan V, Morville P, Dinh-Xuan AT. Echocardiographic investigation of inhaled nitric oxide in newborn babies with severe hypoxaemia. Lancet 1994; 344: 303-305
106 Finer NN, Etches PC, Kamstra B, Tierney AJ, Peliowski A, Ryan CA. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994; 124: 302-308
107 Kinsella JP, Neish SR, Ivy DD, Shaffer E, Abman SH. Clincal responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 1993; 123: 103-108
108 Feusner JH. Normal and abnormal bleeding times in neonates and young children utilizing a fully standardized template technique. Am J Clin Pathol 1980; 74: 73-77
109 Andrew M, Castle V, Mitchell L, Paes B. A modified bleeding time in the infant. Am J Hematol 1989; 30: 190-191
110 Andrew M, Paes B, Bowker J, Vegh P. Evaluation of an automated bleeding time device in the newborn. Am J Hematol 1990; 35: 275-277
111 Andrew M. Platelets in newborns: physiology and pathology. In: Luban N. (ed.) Transfusion Sciences. 12. Pergamon Press; Elmsford, NY: 1991. pp 207-230
112 Fernandez F, Gaudable C, Sie P. et al. Low hematocrit and prolonged bleeding time in uraemic patients: Effect of red cell transfusions. Br J Haematol 1985; 59: 139-148 Abstract
113 Gerrard J, Docherty J, Israels S. et al. A reassessment of the bleeding time: Association of age, hematocrit, platelet function, von Willebrand factor, and bleeding time thromboxane B2 with the length of the bleeding time. Clin Invest Med 1989; 12: 165-171
114 Aarts PA M M, Bolhuis PA, Sakariassen KS, Heethaar RM, Sixma JJ. Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood 1983; 62: 214-220
115 Sanders J, Holtkamp C, Buchanan G. The bleeding time may be longer in children than in adults. Am J Ped Hem One 1990; 12: 314-318
116 Lindblad B, Bergqvist D. Aggressive or conservative treatment in subclavian vein thrombosis. In: Eklof B, Gjores J, Thulesius O, Bergqvist D. (eds.) Controversies in the Management of Venous Disorders. Butterworth & Co; London: 1989. pp 141-158
117 De Stefano V, Leone G, Carolis M. et al. Antithrombin HI in fullterm and preterm newborn infants: Three cases of neonatal diagnosis of AT III congenital defect. Thromb Haemostas 1987; 57: 329-331
118 Mannucci P, Tripodi A, Bertina R, Protein S. deficiency associated with “juvenile” arterial and venous thromboses. Thromb Haemostas 1986; 55: 440
119 Hull R, Raskob G, Hirsh J. et al. Continuous intravenous heparin compared to intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109-1114
120 Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2: 1293-1296
121 Hull R, Raskob G, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264
122 Anonymous. Hirsh J, Genton E, Hull R. (eds.) Venous Thromboembolism. Grune and Stratton; New York: 1981. pp 63-66
123 Norotte G, Glorion C, Rigault P. et al. Complications thrombo- emboliques en orthopedie pediatrique. Recueil “multicentrique” de 33 observations Chir Pediatr 1989; 30: 193-198
124 Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979; 76: 1218-1222
125 Lindahl U, Backstrom G, Hook M, Thunberg L, Fransson L, Linker A. Structure of the antithrombin-binding site of heparin. Proc Natl Acad Sci USA 1979; 76: 3198-3202
126 Casu B, Oreste P, Torri G. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin Ill-binding sequence. Biochem J 1981; 197: 599-609
127 Choay J, Lormeau JC, Petitou M, Sinay P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci 1981; 370: 644-649
128 Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thrombos Haemostas 1986; 12: 39-57
129 Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343
130 Schmidt B, Mitchell L, Ofosu F, Andrew M. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988; 112: 641-643
131 Schmidt B, Buchanan M, Ofosu F, Brooker L, Hirsh J, Andrew M. Antithrombotic properties of heparin in a neonatal piglet model of thrombin induced thrombosis. Thromb Haemostas 1988; 60: 289-292
132 Andrew M, Ofosu F, Schmidt B, Brooker L, Hirsh J, Buchanan M. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res 1988; 52: 517-527
133 Poller L. INR-calibration of the therapeutic range. In: Wessler S, Becker C, Nemerson Y. (eds.) The New Dimensions of Warfarin Prophylaxis. Plenum Press; New York: 1987. pp 95-112
134 Andrew M, Marzinotto V, Brooker L. et al. Oral anticoagulant therapy in pediatric patients: A prospective study. Thromb Haemostas 1994; 71: 265-269
135 Hirsh J. Oral anticoagulant drugs. Review article N Engl J Med 1991; 324: 1865-1875
136 Massicotte M, Marzinotto V, Adams M, Vegh P, Mitchell L, Andrew M. Coumarin suppresses thrombin regulation to a greater extent in children compared to adults. Thromb Haemostas. 1995 in press
137 Massicotte P, Marzinotto V, Vegh P, Adams M, Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr. submitted
138 Leaker MT, Nitchmann E, Benson L, Mitchell L, Andrew M. Thrombolytic therapy in pediatric patients. Thromb Haemostas. 1995 in press
139 Corrigan J, Jeter M. Histidine-rich glycoprotein and plasminogen plasma levels in term and preterm newborns. Am J Dis Child 1990; 144: 825-828
140 Andrew M. The hemostatic system in the infant. In: Nathan D, Oski F. (eds.) Hematology of Infancy and Childhood. 4. W.B. Saunders; Philadelphia: 1992. pp 115-154
141 Massicotte P, Marzinotto V, Adams M, Vegh P, Brooker L, Andrew M. Enhanced prothrombin regulation during warfarin therapy in children compared to adults. Blood. submitted